Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , trigubas derinys terapija), kaip papildoma priemonė kartu su dieta ir fiziniais pratimais pacientams, nepakankamai kontroliuojama, jų maksimali toleruojama dozė metforminas ir sulfonilkarbamido dariniai. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ir 5. 1, jei yra duomenų apie skirtingus derinius).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

billev pharma aps - lutetium (177lu) chloride - radionuklidų vaizdavimas - terapiniai radiofarmaciniai preparatai - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , trigubas derinys terapija), kaip papildoma priemonė kartu su dieta ir fiziniais pratimais pacientams, nepakankamai kontroliuojama, jų maksimali toleruojama dozė metforminas ir sulfonilkarbamido dariniai. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

accord healthcare b.v. - telmisartanas/hidrochlorotiazidas - tabletės - 40 mg/12,5 mg; 80 mg/12,5 mg; 80 mg/25 mg - telmisartan and diuretics

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

tad pharma gmbh - telmisartanas/hidrochlorotiazidas - tabletės - 80 mg/12,5 mg; 40 mg/12,5 mg; 80 mg/25 mg - telmisartan and diuretics

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

sia ingen pharma - telmisartanas/hidrochlorotiazidas - tabletės - 80 mg/25 mg; 80 mg/12,5 mg - telmisartan and diuretics

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

sandoz d.d. - telmisartanas/hidrochlorotiazidas - dengtos tabletės - 80 mg/25 mg; 40 mg/12,5 mg; 80 mg/12,5 mg - telmisartan and diuretics

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva b.v. - telmisartanas/hidrochlorotiazidas - tabletės - 80 mg/12,5 mg - telmisartan and diuretics

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

rp būve ltd., krustpils street 54e, lv-1057 riga (latvija). - benzil-c12-c16-alkildimetilchloridas, alkil-c12-c16-dimetilbenzilamonio chloridas; benzil-c12-c16-alkildimetilchloridas, alkil-c12-c16-dimetilbenzilamonio chloridas - veikliosios medžiagos cas nr.: 68424-85-1, eb nr.: 270-325-2, veikliosios medžiagos pavadinimas: benzil-c12-c16-alkildimetilchloridas, alkil-c12-c16-dimetilbenzilamonio chloridas, koncentracija: 1% , veiklioji; veikliosios medžiagos cas nr.: 68424-85-1, eb nr.: 270-325-2, veikliosios medžiagos pavadinimas: benzil-c12-c16-alkildimetilchloridas, alkil-c12-c16-dimetilbenzilamonio chloridas, koncentracija: 1% , veiklioji - dezinfekantai ir algicidai, kurie nėra skirti tiesioginiam žmonių ar gyvūnų naudojimui